Mark J. Ratain to Etoposide
This is a "connection" page, showing publications Mark J. Ratain has written about Etoposide.
Connection Strength
1.390
-
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9.
Score: 0.275
-
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
Score: 0.128
-
Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother Pharmacol. 1994; 34 Suppl:S64-8.
Score: 0.111
-
New perspectives on the toxicity of etoposide. Semin Oncol. 1992 Dec; 19(6 Suppl 13):78-83.
Score: 0.103
-
Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst. 1991 Nov 06; 83(21):1560-4.
Score: 0.095
-
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 Aug; 9(8):1480-6.
Score: 0.093
-
Dose reduction of etoposide in jaundiced patients. J Clin Oncol. 1990 Dec; 8(12):2088-9.
Score: 0.089
-
Etoposide pathway. Pharmacogenet Genomics. 2009 Jul; 19(7):552-3.
Score: 0.081
-
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther. 1989 Mar; 45(3):226-33.
Score: 0.079
-
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
Score: 0.077
-
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov; 70(5):1412-7.
Score: 0.072
-
Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May; 19(2):171-7.
Score: 0.046
-
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25.
Score: 0.035
-
Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol. 1996; 39(1-2):61-6.
Score: 0.032
-
A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther. 1995 Mar; 57(3):325-34.
Score: 0.030
-
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst. 1993 Feb 03; 85(3):217-23.
Score: 0.026
-
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemother Pharmacol. 2009 Apr; 63(5):881-7.
Score: 0.019